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p38 MAPKPKC activation by combining TPA with sodium butyrate (T/B) represents the most effective and widely used
strategy to induce the Epstein–Barr virus (EBV) lytic cycle. The results obtained in this study show that novel
PKCθ is involved in such process and that it acts through the activation of p38 MAPK and autophagy induction.
Autophagy, a mechanism of cellular defense in stressful conditions, is manipulated by EBV to enhance viral
replication. Besides promoting the EBV lytic cycle, the activation of p38 and autophagy resulted in a pro-
survival effect, as indicated by p38 or ATG5 knocking down experiments. However, this pro-survival role was
counteracted by a pro-death activity of PKCθ, due to the dephosphorylation of AKT. In conclusion, this study re-
ports, for the ﬁrst time, that T/B activates a PKCθ-p38 MAPK axis in EBV infected B cells, that promotes the viral
lytic cycle and cell survival and dephosphorylates AKT, balancing cell life and cell death.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Protein kinases C (PKCs) are serine/threonine kinases that regulate
many cellular functions, in cell type-speciﬁcmanner, andwhose activity
is in turn regulated by serine/threonine and tyrosine phosphorylation
[1–3].
PKCs include several isoforms classiﬁed into three major subgroups:
classical, novel and atypical PKCs. The ﬁrst two groups are activated by
phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate (TPA),
whichmimics the effect of diacylglycerol (DAG), the degradation product
of phoshatidylinositol, the conventional activator of the classical and
novel PKCs. Differently from the classical PKCs, that require the presence
of calcium, novel PKCs are calcium independent [4,5]. Finally, the atypical
PKCs do not require neither DAG nor calcium, being phosphatidylserine
[6] sufﬁcient for their activation [7]. Besides the differences in their activa-
tion, PKC isoforms differ in their structure, tissue distribution and subcel-
lular localization [8,9]. The latter is inﬂuenced by the activation status and
by the interaction with molecules [10] such as RACKs/RICKs (receptorsvirus;p38MAPK,p38mitogen-
K, extracellular signal-regulated
;p62,sequestosome1/SQSTM1;
ggioni),for activated/inactive kinase) [11,12], PICK1 (protein interacting with
C-kinase-1) [13,14] and STICKs (substrates interacting with C kinase)
[15].
Activated PKCs interact with signaling pathways that regulate
cell survival and differentiation such as MEK–ERK, Raf1 and c-Jun
[16] as well as STAT1, STAT3 and NF-κB [17–22]. In particular, PKC
theta (PKCθ), a member of the novel PKCs, has been shown to regu-
late the activation of MKK4, a kinase that acts upstream of p38 and
JNK MAPK in T lymphocytes [23,24], and is involved in PMA-mediated
NF-κB activation also in B cells [25]. The treatment with TPA, by strongly
activating PKCs, efﬁciently induces the Epstein–Barr virus (EBV) lytic
cycle in cells in which the virus establishes a latent infection [26–29].
EBV is an oncogenic virus, associated with several human cancers,
such as Burkitt's lymphoma (BL), in which the majority of cells harbor
a latent infection in-vivo. The TPA-mediated EBV lytic cycle activation
can be potentiated by its combination with sodium butyrate (T/B) [30,
31], that has been shown to differently inﬂuence PKC activation [32].
PKC activation is also involved in Ca ionophore [33] and nocodazole
mediated EBV lytic cycle activation [34]. In particular, a role for the
novel PKCs has been demonstrated in the histone deacetylase medi-
ated EBV reactivation from latency, as indicated by the use of rottlerin, a
novel PKC speciﬁc inhibitor [35]. However, it has been reported that the
EBV lytic cycle can be triggered, in some instances, independently of
PKC activation [36].
We have previously shown that PKC activity is required for EBV
infection of human B cells [37] and, in this study, we investigated the
PKC isoform/s activated by T/B in the EBV-infected B cells, their role
and the mechanisms through which they induce the viral lytic cycle.
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played an essential role in the EBV lytic cycle induction. Our's and
other's laboratories have recently demonstrated that autophagy pro-
motes EBV replication [38,39] and since PKCθ is required for autophagy
induction during Endoplasmic Reticulum (ER) stress [40,41], we next
investigated whether PKC theta could promote the EBV lytic cycle
through autophagy induction. Moreover, since p38 MAPK, that plays
an essential role in EBV reactivation from latency [42], is involved in
autophagy induction [43,44] and since p38 phosphorylation may be
mediated by PKCθ in other cell types [23,24], we then asked if T/B could
activate a PKCθ-p38 axis in EBV infected B cells, promoting the viral lytic
cycle through autophagy induction. The autophagic process was moni-
tored by the biochemical analysis of autophagic markers LC3II (lipidated
formof LC3 that is formedduring the autophagic process) and p62 (a pro-
tein speciﬁcally degraded through autophagy) [45].
It has been demonstrated that the activation of novel PKCs, such
as PKC delta (PKC δ), can induce both cell death and cell survival
[46]. Similarly, here we found that PKCθ activation resulted in a
pro-survival effect due to p38 and autophagy induction but, on the
other hand, it was involved in the dephosphorylation of AKT mediated
by T/B. PKCs have been previously reported to mediate the inhibition of
AKT pathway in the course of TPA treatment, in keratinocytes [47]. AKT
represents an important pro-survival pathway in BL cells [48] as
well as in other lymphoma's cells [49]. Understanding the role and
the mechanism/s through which the different PKCs act in regulating
viral replication and cell survival is of pivotal importance to develop
speciﬁc inhibitors, to be used in the clinical practice against EBV
associated malignancies.2. Materials and methods
2.1. Cell cultures and reagents
B95-8 [50], P3HR1 [51], Akata [52] and Raji are EBV positive B cell
lines [53], 293-EBVderived from293 cell lines and are stably transfected
with B95.8 genomes (kindly provided by H.J. Delecluse) [54]. Cells were
grown in RPMI 1640 (Sigma-Aldrich R0883) supplemented with 10%
heat inactivated fetal bovine serum (FBS) (EuroClone ECLS0 180L),
glutamine (2 mM) streptomycin (100 g/ml) and penicillin (100 U/ml
Aurogene AU-L0022-100), in 5% CO2 at 37 °C. The EBV lytic cycle was
induced with TPA (12-O-tetradecanoylphorbol13-acetate) (Sigma-
Aldrich P1585) and sodium butyrate (Sigma-Aldrich B5887) were
used at a ﬁnal concentration of 40 ng/ml and 6 mM in B95-8 cells,
20 ng/ml and 3mM in P3HR1 cells, and by anti-IgG (50 μg/ml, Millipore
56961) crosslinking in Akata cells. The cells were pre-treated with p38
inhibitor (SB203580, Sigma-Aldrich S8307), JNK inhibitor (SP600125,
Santa Cruz sc-200635), ERK inhibitor (PD98059, Sigma-Aldrich P215)
and PI3K/ATK inhibitor (LY294002, Sigma-Aldrich P0037) at 20 μM for
30 min and then, treated with TPA and sodium butyrate. Novel PKC
inhibitor rottlerin (Santa Cruz sc-3550)was added at ﬁnal concentrations
of 5, 10, 20 μM for 1 h before transfection.2.2. Virus production from 293-EBV cell line and Raji superinfection
293-EBV cells were grown in six-well cluster plates, pretreated
with different concentrations of rottlerin for 1 h and then, were
transfected with the expression plasmid containing the gene for
BZLF1 (0.5 μg each/well) (pBZLF1) (p509), (kindly provided by
Prof. Delecluse), by using lipid micelles (Metafectene; Biontex) to
induce lytic replication [54,55]. Four days after transfection, culture
supernatants were harvested, ﬁltered through a 0.45 μm and used to
superinfect Raji cells (500 μl supernatant/105 Raji cells). Three days
after superinfection Raji cells were analyzed by FACS and scored for
GFP expression.2.3. Western blot analysis
Cells were lysed in modiﬁed RIPA buffer (150 mM NaCl, 1% NP40,
50 mM Tris–HCl pH 8, 0.5% deoxycholic acid, 0.1% SDS, 1% Triton
X-100 protease and phosphatase inhibitors) and 30 μg of each lysate
were loaded on 4–12% NuPage Bis Tris gels (Life Technologies
NP0323BOX) electrophoresed and transferred to Nitrocellulose
membrane (Whatman, GE Healthcare 10401196). Membranes
were blocked for 30 min at RT in PBS containing BSA 3% and 0.2%
Tween 20, then incubated with primary antibody overnight at 4 °C,
washed three times with PBS 0.2% Tween 20 and probed with ap-
propriate secondary HRP-conjugated secondary antibody (Santa
Cruz Biotechnologies). After 3 washes as described before, the mem-
branes were subjected to ECL reaction with a blotting substrate
(Advansta 12045-D20).
2.4. Antibodies
For Western blot analysis, the following primary antibodies were
used: rabbit polyclonal anti-LC3 (1:1000) (Novus Biologicals NB100-
2220SS), rabbit polyclonal anti-phospho PKC-theta (1:200) (Cell Signal-
ing 9377P), rabbit polyclonal anti-p38 (1:500) (Cell Signaling 9212),
rabbit polyclonal anti-phospho p38 (1:500) (Cell Signaling 4631P), rab-
bit polyclonal anti-AKT (1:500) (Cell Signaling 9272S), rabbit polyclonal
anti-phospho AKT (Cell Signaling 4060S) (1:500), rabbit polyclonal
anti-phospho JNK (1:500) (Cell Signaling 4668P), rabbit polyclonal
anti-JNK (1:500) (Cell Signaling 9258P), rabbit polyclonal anti-ERK
(1:500) (Santa Cruz sc-93 mixed with Santa Cruz sc-154), rabbit
polyclonal anti-phospho ERK (1:300) (Cell Signaling sc-7383), rab-
bit polyclonal anti-cleaved PARP p85 (1:1000) (Promega G7341),
rabbit polyclonal anti-ATG5 (1:1000) (Novus Biological NB110-
53818), mouse monoclonal anti BFRF1 was developed in our lab (1:50)
[56], mouse monoclonal anti-ZEBRA (1:100) (Santa Cruz sc-53904),
mouse monoclonal anti-p62 (1:1000) (BD Transduction Laboratories
610833), mouse monoclonal anti-RTA (1:500) (Argene), mouse
monoclonal anti-EA-D (1:1000) (Millipore 8186), mouse monoclonal
anti-β-actin (1: 10000) (SIGMA A2228), mouse monoclonal anti-
GAPDH (1:1000) (Santa Cruz sc-137179), mouse monoclonal anti-
tubulin (Sigma-Aldrich T5168) (1:1000).
Goat anti-rabbit IgG-horseradish peroxidase HRP (1:104)
(Santa Cruz sc-2004) and goat anti-mouse IgG-horseradish perox-
idase HRP (1:104) (Santa Cruz sc-2005) were used as secondary
antibodies. All of the primary and secondary antibodies used in
this study were diluted in a PBS-0.2% Tween 20 solution contain-
ing 3% BSA.
2.5. Immunoﬂuorescence
Cells were seeded onmultispot slides and ﬁxed in 2% paraformalde-
hyde for 30 min at RT, washed 3 times in PBS and permeabilized with
0.5% Triton X-100 for 5min at RT; then blockedwith a solution contain-
ing 3% BSA 1% glycin for 30 min at RT. Samples were incubated with
primary antibodies for 1 h at RT then, after washing in PBS, the ap-
propriated conjugated secondary antibodies were added and ﬁnally
the samples were stained with DAPI (Sigma-Aldrich D9564). Micro-
scope slides were mounted using PBS-glycerol 1:1 and visualized by a
Apotome axio observer Z1 inverted microscope (Zeiss Oberkochen,
Germany), equipped with an Axiocam MRM Rev.3 camera at 40×
magniﬁcation.
For immunoﬂuorescence analysis the following primary anti-
bodies were diluted in PBS as the following: rabbit polyclonal anti-
phospho-PKCμ (Cell Signaling) rabbit polyclonal anti-phospho PKCαβ
(1:20) (Cell Signaling 9375), rabbit polyclonal anti-phospho PKCδ
(1:20) (Cell Signaling 9374), rabbit polyclonal anti-phospho PKCθ
(1:20) (Cell Signaling 9377P), mouse monoclonal anti-BFRF1
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Secondary antibodies were diluted in PBS as the following:
TRITC-conjugated goat anti-rabbit (1:300) (Jackson 111-025-003),
Alexa Fluor-488 conjugated goat anti-rabbit (1:200) (Invitrogen
A11008), Cy3 conjugated sheep anti-mouse (1:1000) (Jackson
515-165-062).2.6. Genes knockdown by siRNA
The knockdown of PKCθ, p38 and ATG5 was performed by specif-
ic small interfering RNA according to the manufacturer's instruc-
tions (Santa Cruz sc-36247, sc-29433, sc-41445 respectively).
Brieﬂy the day before transfection 4 × 105cells were seeded in
six-well culture plates in a RPMI medium without antibiotics. Subse-
quently 100 pmol of speciﬁc small interfering RNA (siRNA duplex)
or non-targeting (scramble) siRNA and 10 μl of transfection reagent
(Lipofectamin 2000 Life Technologies 11668027) were diluted in
Opti-MEM medium (Life Technologies 31985062) and added to
the cells according to the manufacturer's instruction. To evaluate
transfection efﬁciency a ﬂuorescein conjugate control siRNA (Santa
Cruz sc-36869) was also included in each experiment. The cells
were treated with TPA and sodium butyrate 24 h after transfection
and collected the day after treatment. Finally cells were counted
by trypan-blue exclusion assay using a hemocytometer and pel-
leted for protein extraction. Each experiment was performed in
triplicate.2.7. Statistics
All experiments unless differently indicated were performed at least
three times. All the experimental results were expressed as arithmetic
mean ± standard deviation (s.d.). Student's t-test was used for statisti-
cal signiﬁcance of the differences among treated groups. Statistical anal-
ysis was performed using analysis of variance at 5% (p = 0.05) or 1%
(p = 0.01).Fig. 1. EBV replication induced by T/B is dependent on novel PKC activity. (A) P3HR1 BL cells w
concentration of rottlerin, a PKCnovel speciﬁc inhibitor (from 5 μMto 20 μM) and the expression
was induced in 293-EBV cells by pBZLF1 (p509) transfection in the presence or in the absence o
analyzed. (C) Percentage of GFP-positive Raji cells super-infected with the supernatant of 293-E
increasing concentration of rottlerin. A representative experiment out of three is shown.3. Results
3.1. Novel PKC activity is required for T/B mediated EBV lytic cycle
activation
We investigated the role of the novel PKCs in P3HR1 BL cells induced
to lytic cycle by T/B. To this aim, the cells were treated with T/B for 24 h,
in the presence or in the absence of rottelerin, a novel PKC speciﬁc
inhibitor ([57,58]). As shown in Fig. 1A, the expression level of EA-D, an
early lytic EBV antigen, progressively decreased in the presence of an in-
creasing amount of rottlerin, indicating that novel PKCs play an essential
role in the induction of EBV lytic cycle by T/B, in BL cells. Next, rottlerin
was used to inhibit EBV replication also in 293-EBV cells in which recom-
binant EBV-B95-8 genomeswere stably transfected [54]. To induce a virus
production, 293-EBV cells were transiently transfected with a plasmid
which encodes the ZEBRA protein. After 96 h, the virus supernatants
were used to infect the Raji cells. Functional viral titers were determined
via GFP expression of infected Raji cells. The number of green Raji units
per milliliter was calculated as a measurement of the infectious particle
concentration in virus stock [55]. As shown in Fig. 1B, the expression of
RTA, an immediate early EBV antigen, whose expression is soon induced
by ZEBRA transfection, was strongly reduced in the presence of rottlerin
[59]. Finally, to assesswhether the inhibition of novel PKCswould also im-
pair viral production, the supernatant of 293-EBV cells, induced to lytic
cycle by ZEBRA transfection, in the presence or in the absence of increas-
ing amount of rottlerin, was used to superinfect Raji cells. We found that,
accordingly to the inhibition of EBV lytic antigen expression, rottlerin
strongly inhibited the 293-EBV supernatant infectivity on Raji cells,
assessed by counting the GFP-positive cells by serial dilutions (Fig. 1C).
These results conﬁrm the importance of the novel PKCs in the activation
of EBV lytic cycle.
3.2. PKCθ is involved in EBV reactivation from latency by T/B
P3HR1 cells, treated with T/B to induce EBV reactivation from laten-
cy, were analyzed by immunoﬂuorescence assay (IFA), to investigate
the activation of novel (θ and δ), classical (α/β), and atypical (μ) PKCs,
using polyclonal antibodies directed against the phosphorylated formsere induced to lytic cycle by T/B for 24 h in the presence or in the absence of increasing
of the EBV lytic antigen EA-Dwas evaluated byWestern blot analysis. (B) Viral replication
f increasing concentration of rottlerin and the expression of the EBV lytic antigen RTA was
BV cells induced to lytic cycle by pBZLF1 transfection, in the presence or in the absence of
Fig. 2. PKCθ is themost activated PKC isoform that plays an essential role in EBV lytic cycle. (A) Immunoﬂuorescence analysis (IFA) showing ZEBRA EBV lytic antigen expression and PKCθ,
δ, α/β and μ activation in EBV infected B cells undergoing viral replication by T/B. (B) Double IFA showing PKCθ activation (stained in green) and BFRF1 EBV lytic antigen expression
(stained in red), in B95-8, P3HR1 andAkata cells untreated or induced to lytic cycle by T/B or by anti-IgG, for 24 h. (C) B95-8 cells knockeddown for PKCθ or scramble treatedwere exposed
to T/B and the expression of phosphorylated PKCθ uncleaved (PKCθUn) or cleaved (PKCθCl) forms as well as ZEBRA EBV lytic antigen was analyzed byWestern blotting. A representative
experiment is shown and the means plus standard deviations of the densitometric analysis of three independent experiments is also reported.
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detecting the expression of the EBV early antigen BFRF1 (Fig. 2A). We
found that PKCθ and to a much lesser extend δ, α/β or μ PKC isoforms
were activated upon 24 h of T/B treatment (Fig. 2A). Similar results
were obtained in the marmoset B lymphoblastoid B95-8 cells, under-
going EBV lytic cycle by the same treatment (data not shown). We nextFig. 3. p38MAPK is phosphorylated and promotes the EBV lytic cycle by inducing autophagy in
JNK1/2 and ERK1/2 MAPKs was evaluated byWestern blot analysis. (B) B95-8 cells were treate
(SP, PD and SB, respectively) and ZEBRA EBV lytic antigen as well as the autofagic markers LC
included as control. A representative experiment and the ratio of the phosphorylated versus the t
of the speciﬁc proteins on actin of three independent experiments is also reported.performed a double IFA for BFRF1 and PKCθ to evaluate, at a single cell
level, whether PKCθ was speciﬁcally activated in cells undergoing EBV
replication, either spontaneously or upon T/B treatment. The results
shown in Fig. 2B indicate that in the great majority of P3HR1 and B95-8
cells expressing BFRF1, PKCθwas strongly activated and that it wasmost-
ly localized in the cell nuclei. Finally, as shown in the same ﬁgure, weB95-8 cells. (A) B95-8 cells were treatedwith T/B for 24 h and the phosphorylation of p38,
d with T/B in the presence or in the absence of JNK1/2, ERK1/2 and p38, speciﬁc inhibitors
3I/II and p62 were analyzed by Western blot. Total JNK1/2, ERK1/2, p38, and actin were
otal molecules are shown. The means plus standard deviations of the densitometric analysis
Fig. 4. p38MAPK is phosphorylated and promotes the EBV lytic cycle by inducing autophagy in P3HR1 cells. (A) P3HR1 cells were treatedwith T/B for 24 h and the activation of p38MAPK
was analyzed byWestern blot. (B) P3HR1 cells were treatedwith T/B in the presence or in the absence of p38 inhibitor and ZEBRA EBV lytic antigen aswell as the autofagicmarkers LC3I/II
and p62 were analyzed by Western blot. Total p38 and actin were included as control. A representative experiment and the ratio of the phosphorylated versus the total molecule are
shown. The means plus standard deviations of the densitometric analysis of the speciﬁc proteins on actin of three independent experiments is also reported.
1590 R. Gonnella et al. / Biochimica et Biophysica Acta 1853 (2015) 1586–1595found that PKCθ was activated also in the Akata cells undergoing spon-
taneous replication or induced to lytic cycle by anti-IgG cross-linking.
These results indicate that the activation of the EBV lytic cycle occursFig. 5. PKCθ induces the EBV lytic cycle through p38 MAPK and autophagy activation. (A) B95-8
pp38, EA-D EBV lytic antigen, LC3II and p62 were analyzed byWestern blot. Tubulin was includ
deviations of the densitometric analysis of the speciﬁc proteins on tubulin of three independen
with T/B were analyzed for the expression of ZEBRA, by immunoﬂuorescence assay (IFA).concomitantly with PKCθ activation in several cell types and with differ-
ent lytic cycle inducers. To investigate the speciﬁc role of PKCθ in EBV
lytic cycle, this novel PKC isoform was knocked down by a speciﬁccells knocked down for PKCθ or scramble treated were exposed to T/B for 24 h and PKCθ,
ed as loading control. A representative experiment is shown. (B) Themeans plus standard
t experiments is also reported. (C) B95-8 cells knocked down for PKCθ or p38 and treated
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early lytic EBV antigen ZEBRA was evaluated by Western blot analysis.
We found that PKCθ knocking down strongly reduced ZEBRA expression,
in comparison to scramble treated cells (Fig. 2C). Of note, the activation of
PKCθ by T/B resulted in the appearance of a cleaved formof thismolecule,
as described for other activated PKCs [60].
3.3. p38 MAPK plays a positive role in EBV replication and affects the
autophagic pathway in EBV-infected B cells treated with T/B
MAPK kinases are reported to be activated in EBV-infected Raji BL
cells, in which an abortive lytic cycle was induced by T/B [42]. In thisFig. 6. PKCθ balances pro-survival and pro-death pathways in B95-8 cells. B95-8 cells knocked d
was evaluated by Trypan blue assay (*p=0.02) and (B) PARP cleavage together with the ZEBRA
down for ATG5or for PKCθ or scramble treatedwere exposed to T/B for 24h and (C) cell survival
EBV lytic proteinwere assessed byWestern blot analysis. (E) The level of AKT phosphorylationw
for 24 byWestern blot analysis. (F) The level of AKT phosphorylation was evaluated in B95-8 ce
blot analysis. Total AKT and/or GAPDH were also included as control. A representative experim
speciﬁc proteins on GAPDH of three independent experiments is also reported.study we investigated whether these kinases were activated also in
the B cells able to support a complete EBV lytic program, upon T/B treat-
ment. The results shown in Fig. 3A indicate that p38MAPK and to a less-
er extent JNK and ERK phosphorylationswere induced by T/B, after 24 h
of treatment. The role of these kinases in the EBV lytic cycle was then
evaluated by treating B95-8 cells with T/B in the presence or in the ab-
sence of p38, JNK or ERK inhibitors, SB203580, SP600125 or PD98059,
respectively. According to the results previously obtained in Raji cells
[42], ZEBRA expression was more strongly reduced by SB203580 in
comparison with SP600125 or PD98059, indicating that p38 MAPK
plays a major role in the activation of the EBV lytic program in B95-8
cells (Fig. 3B). Looking for a mechanism/s underlying the EBV lyticown for p38 MAPK or scramble treated were exposed to T/B for 24 h and (A) cell survival
EBV lytic protein and p38were investigated byWestern blot analysis. B95-8 cells knocked
was evaluated byTrypanblue assay (**p=0.02) and (D) PARP cleavage togetherwith RTA
as evaluated in B95-8 cells knockeddown for PKCθ or scramble treated and exposed to T/B
lls knocked down for p38MAPK or scramble treated and exposed to T/B for 24 byWestern
ent is shown and the means plus standard deviations of the densitometric analysis of the
Fig. 7. AKT inhibition reduces the EBV lytic antigen expression and slightly affects autoph-
agy induced by T/B in PKCθ knocked down B95-8 cells. A) B95-8 cellswere induced to lytic
cycle by T/B in the presence or in the absence of Ly 294002 AKT inhibitor (Ly) and the
expression of the EBV lytic antigen BFRF1 was evaluated by Western blot analysis.
B) B95-8 cells silenced for PKCθ were treated with T/B in the presence or in the absence
of Ly 294002 AKT inhibitor and the expression level of the autophagic marker p62 was
evaluated by Western blot analysis. A representative experiment is shown and the
means plus standard deviations of the densitometric analysis of the speciﬁc proteins on
actin of three independent experiments is also reported.
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of autophagy, whose positive role in EBV replication has been recently
demonstrated by our's and other's laboratories [38,39]. We found that
the level of the lipidated form of LC3 (LC3II), arising during the autoph-
agic process induced by T/B, was strongly reduced by SB203580, p38 in-
hibitor, concomitantlywith the reduction of ZEBRA expression (Fig. 3B),
suggesting that p38 MAPK is involved in autophagy induction by T/B.
ZEBRA expression and LC3II level were less inﬂuenced by PD98059
and SP600125 (Fig. 3B), indicating that ERK and JNK play a minor role
in both lytic cycle and autophagy activation. Since LC3II is formed and
degraded through autophagy, it does not allow by itself to evaluate
the completeness of the process. So, we then analyzed the expression
level of p62, a protein that represents a read-out of a bona ﬁde autoph-
agic process. As shown in Fig. 3B, p62 level increased in the presence of
SB203580 in combinationwith T/B, further supporting that idea that p38
is involved in the autophagy induction. The importance of p38 MAPK in
the EBV lytic cycle activationwas then conﬁrmed in the P3HR1BL cells in-
duced to lytic cycle by T/B treatment (Fig. 4A and B).
3.4. A PKCθ-p38 MAPK axis promotes EBV-lytic cycle through autophagy
induction
Since novel PKCs can act upstream of MAPKs [61,62], we then inves-
tigated whether the phosphorylation of p38 MAPK could depend on
PKCθ activation and both kinases could promote the EBV lytic cycle,
through autophagy induction. To this aim, the level of p38 phosphoryla-
tion as well as the autophagic markers LC3 I/II and p62 were evaluated
in B95-8 knocked down for PKCθ, byWestern blot analysis. PKCθ silenc-
ing was revealed by the reduction of its cleaved form, known to be pro-
duced during T/B treatment [60], (Fig. 5A and B). We found that p38
phosphorylation and LC3II expression level were reduced while p62 ac-
cumulated in PKCθ knocked down cells, in comparison with the scram-
ble treated control, upon T/B treatment (Fig. 5A and B), as a result of an
autophagic block. Concomitantly to the block of autophagy, the expres-
sion of the EBV early lytic protein EA-D was reduced by PKCθ knock
down (Fig. 5A and B). All together these data indicate that PKCθmediate
the phosphorylation of p38 MAPK which, in turn, promoted the EBV
lytic cycle by inducing autophagy. A reduction of the percentage of
ZEBRA expressing cells was then observed by IFA in B95-8 knocked
down PKCθ or p38 MAPK, in comparison to scramble or control cells,
(Fig. 5C), conﬁrming that both kinases play a positive role in the EBV
reactivation from latency.
3.5. PKCθ at the cross-roads between cell survival and cell death
PKCθ phosphorylation by T/B induces p38 MAPK activation that in
turn promotes autophagy in B95-8 cells. p38 has been reported to pro-
mote cell survival during the activation of the EBV lytic cycle [42] and
autophagy is also usually a pro-survival mechanism, especially during
stressful conditions, such as during treatment with cytotoxic therapies
[63,64]. Based on this knowledge, we next investigated the role of p38
in cell survival, by knocking down this molecule with speciﬁc siRNA.
We found that cell survival was reduced and PARP cleavage increased
in p38 knocked down cells treated with T/B in comparison with scram-
ble control (Fig. 6A and B). A similar effect on cell survival and PARP
cleavage was then obtained by knocking down ATG5, an essential au-
tophagic gene (Fig. 6C and D), conﬁrming the pro-survival role of both
p38 and autophagy activation during T/B treatment. Surprisingly, the
percentage of cell survival and PARP cleavage did not increase in cells
knocked down for PKCθ, in comparison with the scramble control,
upon T/B treatment (Fig. 6C and D), suggesting that PKCθ, besides
being involved in pro-survival effects, is acting on other/s pathways
that induce cell death. Of note, the silencing of p38, ATG5 and PKCθ re-
duced the EBV immediate early lytic protein expression (Fig. 6B and D),
further supporting the idea that these molecules belong to a common
pathway leading to the EBV lytic cycle activation.Since PKC activation can reduce AKT phosphorylation [47] and AKT
represents an important pro-survival pathway in lymphoma cells [49],
including BL cells [48,49], we next investigated if PKCθ could be
involved in the AKT dephosphorylation mediated by the T/B treatment.
We found that AKT phosphorylation was less affected in PKCθ knocked-
down B95-8 cells, in comparisonwith the scramble control treatedwith
T/B (Fig. 6E), suggesting that PKCθ is able to balance cell survival and cell
death in B cells, in which it promotes the EBV replicative cycle. Differ-
ently from PKCθ, p38 silencing slightly inﬂuenced AKT dephosphoryla-
tion induced by T/B (Fig. 6F), in agreement with the pro-survival role
of p38 in the course of the T/B treatment (Fig. 6A and B). Next, we inves-
tigated the role of AKT in the EBV lytic cycle by inhibiting its activity
with Ly294002 (Ly) in B95-8 cells induced to lytic cycle by T/B. Accord-
ing to previous studies on EBV replication [65,66], we found that Ly re-
duced the expression of BFRF1 EBV lytic antigen, conﬁrming that PI3K/
AKT axis was involved in the induction of the EBV lytic cycle (Fig. 7A).
Finally, we investigatedwhether the dephosphorylation of AKT induced
by PKCθwould contribute to itsmediated autophagy induction in B95-8
cells treated with T/B. At this aim, we inhibited AKT with Ly 294002 in
cells knocked down for PKCθ, before the T/B treatment. The results
reported in Fig. 7B, showing that p62 level was slightly affected by Ly
treatment, suggest that PKCθ-mediated AKT dephosphorylation plays
a minor role on autophagy induction.4. Discussion
In this study, we show that PKCθ is strongly activated in the EBV-
infected cells induced to lytic cycle. Similar to other PKCs, activated
PKCθ migrated at a lower molecular weight representing its catalytic
domain, released from the intramolecular inhibitory domain, cleaved
by caspase activation [67]. Moreover, upon T/B treatment, PKCθ localized
to the nuclei, as other novel PKCs that translocate to the nuclei when ac-
tivated [68]. PKCs have been reported to reduce Akt phosphorylation in
Fig. 8. Schematic model describing the pathways activated or inhibited downstream of
PKCθ.
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was dephosphorylated by T/B, dependently on PKCθ activity. Several
drugs can induce cancer cell death through AKT dephosphorylation [69]
and this pathway is reported to be critical also for BL cell survival [47,
48]. While the involvement of the novel PKCs in apoptosis [70–72] has
been extensively studied, their role in the autophagic process has been
only recently begun to be explored [73–75].
Here we show that besides promoting cell death, PKCθ induced au-
tophagy and cell survival by activating p38 MAPK. Autophagy is indeed
a cellular degradative process that helps cells to face stressful condi-
tions, such as in the course of chemotherapy treatments [63]. It could
also be the underlyingmechanism of the p38-mediated pro-survival ef-
fect, previously observed by other authors, during the induction of the
EBV lytic cycle [42]. Finally, autophagy, although subverted by EBV,
was shown to play a positive role in viral lytic cycle [38,39]. In this
studywe found that PKCθ and p38promoted the EBV lytic cycle through
autophagy induction. The PKCθ isoform has been already shown to be
involved in autophagy induction, in the course of ER stress, in other
cell types [40,41]. Differently from EBV, in Kaposi's sarcoma human her-
pesvirus (KSHV) the lytic cycle was induced by PKCδ [76] and ERK acti-
vation [61]. However, autophagy was not investigated in these studies
and, only later on, it has been reported that autophagy enhances KSHV
replication [77]. A PKCδ-JNK axis has been shown to induce autophagy
during hypoxic stressful conditions [78] as well as in the course of
other cellular stresses [74,79]. Moreover, the activation of PKC, induced
by microtubule depolymerization, plays a role in the EBV reactivation
from latency, through the downstream p38 and JNK phosphorylations,
in nasopharyngeal carcinoma cells [34]. However, the involvement of
the speciﬁc PKC isoforms was not investigated. In this study, we found
that T/B activates PKCθ which, besides promoting the EBV lytic cycle,
balances cell survival and cell death, by activating p38 and autophagy
in one hand and by dephosphorylating AKT, on the other hand (Fig. 8).
A better understanding of the mechanisms regulating cell survival and
the switch from latent to lytic cycle of EBV-infected cancer cells could
help ﬁnd new and more effective therapeutic approaches against EBV-
associated malignancies. The ﬁnding that PKCθ is involved in EBV lytic
cycle activation, encourages the searching for speciﬁc inhibitors of this
molecule to control EBV reactivation. For example, sotrastaurin, an inhib-
itor of PKCs, including PKCθ, already experimented in organ transplanta-
tion [80] and very effective in inhibiting HIV reactivation [81] could
have abroader effect in controlling the lytic cycle activationof different vi-
ruses, including EBV, in immuno-compromised patients.Acknowledgements
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